Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Gastrointestinal Surgery
Published in: Journal of Gastrointestinal Surgery 3/2017

01-03-2017 | Original Article

Effect of Oral ω3-Polyunsaturated Fatty Acids as a Complement Management to Control Fistula Output and Inflammation in Patients With Digestive Fistula

Authors: José Luis Martínez-Ordaz, Ilka Boscó-Gárate, Arturo Cérbulo-Vázquez, Lourdes Arriaga-Pizano, Isabel Wong-Baeza, Patricio Sánchez-Fernandez, Constantino López-Macías, Armando Isibasi, Eduardo Ferat-Osorio

Published in: Journal of Gastrointestinal Surgery | Issue 3/2017

Login to get access

Abstract

Background

The presence of digestive fistula involves chronic inflammation and fibrosis. It has been reported that ω3-polyunsaturated fatty acids stimulate the resolution of inflammation.

Aim

Determine if the administration of oral ω3 reduces fistula output and the time required for fistula closure.

Methods

Forty-nine patients with postoperative fistula were randomly divided in two groups: 26 received conventional treatment and 23 received the conventional treatment supplemented with ω3 (540 mg eicosapentaenoic acid and 360 mg docosahexaenoic acid) for 35 days. Patients were monitored daily for fistula output and spontaneous closure. Additionally, serum pro-inflammatory cytokines and C-reactive protein were quantified in four patients with conventional and in seven patients with ω3 treatment.

Results

Patients with ω3 had significantly decreased fistula output from days 2 to 27, compared to control (p < 0.05). Spontaneous fistula closure was achieved in 15 patients (65%) in the ω3 group and in 14 (54%) in the control group. ω3-polyunsaturated fatty intake also decreased the serum concentrations of interleukin-6 and C-reactive protein (p < 0.05).

Conclusions

Our results suggest that ω3 supplementation to conventional medical treatment decreases fistula output and reduces inflammation (interleukin-6 and C-reactive protein), and these effects may increase the efficiency of conventional medical treatment.
Literature
1.
Falconi M, Pederzoli P: The relevance of gastrointestinal fistulae in clinical practice: a review. Gut 2001, 49 Suppl 4:iv2-10.PubMed
2.
3.
Foster CE, 3rd, Lefor AT: General management of gastrointestinal fistulas. Recognition, stabilization, and correction of fluid and electrolyte imbalances. The Surgical clinics of North America 1996, 76(5):1019–1033.CrossRefPubMed
4.
S. J. Dudrick LP: Metabolic consequences of patients with gastrointestinal fistulas. European Journal of Trauma and Emergency Surgery 2011, 37(3):215–225.
5.
Soeters PB, Ebeid AM, Fischer JE: Review of 404 patients with gastrointestinal fistulas. Impact of parenteral nutrition. Ann Surg 1979, 190(2):189–202.CrossRefPubMedPubMedCentral
6.
Lundy JB, Fischer JE: Historical perspectives in the care of patients with enterocutaneous fistula. Clinics in colon and rectal surgery 2010, 23(3):133–141.CrossRefPubMedPubMedCentral
7.
Caccialanza R, Klersy C, Cereda E, Cameletti B, Bonoldi A, Bonardi C, Marinelli M, Dionigi P: Nutritional parameters associated with prolonged hospital stay among ambulatory adult patients. CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne 2010, 182(17):1843–1849.
8.
Kyle UG, Coss-Bu JA: Nutritional assessment and length of hospital stay. CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne 2010, 182(17):1831–1832.
9.
Skovgaard R, Keiding H: A cost-effectiveness analysis of fistula treatment in the abdominal region using a new integrated fistula and wound management system. Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society / WOCN 2008, 35(6):592–595.CrossRef
10.
Dubose JJ, Lundy JB: Enterocutaneous fistulas in the setting of trauma and critical illness. Clinics in colon and rectal surgery 2010, 23(3):182–189.CrossRefPubMedPubMedCentral
11.
Chapman R, Foran R, Dunphy JE: Management of Intestinal Fistulas. American journal of surgery 1964, 108:157–164.CrossRefPubMed
12.
Sheldon GF, Gardiner BN, Way LW, Dunphy JE: Management of gastrointestinal fistulas. Surgery, gynecology & obstetrics 1971, 133(3):385–389.
13.
14.
Hesse U, Ysebaert D, de Hemptinne B: Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data. Gut 2001, 49 Suppl 4:iv11-21.PubMed
15.
Rahbour G, Siddiqui MR, Ullah MR, Gabe SM, Warusavitarne J, Vaizey CJ: A meta-analysis of outcomes following use of somatostatin and its analogues for the management of enterocutaneous fistulas. Ann Surg 2012, 256(6):946–954.CrossRefPubMed
16.
Coughlin S, Roth L, Lurati G, Faulhaber M: Somatostatin analogues for the treatment of enterocutaneous fistulas: a systematic review and meta-analysis. World J Surg 2012, 36(5):1016–1029.CrossRefPubMed
17.
Nubiola P, Badia JM, Martinez-Rodenas F, Gil MJ, Segura M, Sancho J, Sitges-Serra A: Treatment of 27 postoperative enterocutaneous fistulas with the long half-life somatostatin analogue SMS 201–995. Ann Surg 1989, 210(1):56–58.
18.
Aguirre A, Fischer JE, Welch CE: The role of surgery and hyperalimentation in therapy of gastrointestinal-cutaneous fistulae. Ann Surg 1974, 180(4):393–401.CrossRefPubMedPubMedCentral
19.
Owen RM, Love TP, Perez SD, Srinivasan JK, Sharma J, Pollock JD, Haack CI, Sweeney JF, Galloway JR: Definitive Surgical Treatment of Enterocutaneous Fistula: Outcomes of a 23-Year Experience. Arch Surg 2012:1–9.
20.
Draus JM, Jr., Huss SA, Harty NJ, Cheadle WG, Larson GM: Enterocutaneous fistula: are treatments improving? Surgery 2006, 140(4):570–576; discussion 576–578.CrossRefPubMed
21.
Martinez-Ordaz JL, Luque-de-Leon E, Suarez-Moreno RM, Blanco-Benavides R: [Postoperative entero-cutaneous fistula]. Gac Med Mex 2003, 139(2):144–151.PubMed
22.
Wynn TA: Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. The Journal of clinical investigation 2007, 117(3):524–529.CrossRefPubMedPubMedCentral
23.
24.
Endo J, Arita M: Cardioprotective mechanism of omega-3 polyunsaturated fatty acids. Journal of cardiology 2015.
25.
Calder PC: Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? British journal of clinical pharmacology 2013, 75(3):645–662.PubMedPubMedCentral
26.
Serhan CN: Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 2007, 25:101–137.CrossRefPubMed
27.
Serhan CN, Dalli J, Colas RA, Winkler JW, Chiang N: Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochimica et biophysica acta 2015, 1851(4):397–413.CrossRefPubMed
28.
Singer P, Shapiro H, Theilla M, Anbar R, Singer J, Cohen J: Anti-inflammatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective. Intensive care medicine 2008, 34(9):1580–1592.CrossRefPubMed
29.
Calder PC: Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids 2006, 75(3):197–202.CrossRefPubMed
30.
31.
Pluess TT, Hayoz D, Berger MM, Tappy L, Revelly JP, Michaeli B, Carpentier YA, Chiolero RL: Intravenous fish oil blunts the physiological response to endotoxin in healthy subjects. Intensive care medicine 2007, 33(5):789–797.CrossRefPubMed
32.
Ferguson JF, Mulvey CK, Patel PN, Shah RY, Doveikis J, Zhang W, Tabita-Martinez J, Terembula K, Eiden M, Koulman A et al.: Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers. Molecular nutrition & food research 2014, 58(3):601–613.CrossRef
33.
Tang Y, Zhang MJ, Hellmann J, Kosuri M, Bhatnagar A, Spite M: Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes 2013, 62(2):618–627.CrossRefPubMedPubMedCentral
34.
35.
Skulas-Ray AC: Omega-3 fatty acids and inflammation: a perspective on the challenges of evaluating efficacy in clinical research. Prostaglandins & other lipid mediators 2015, 116–117:104–111.
36.
Wang C, Chung M, Lichtenstein A, Balk E, Kupelnick B, DeVine D, Lawrence A, Lau J: Effects of omega-3 fatty acids on cardiovascular disease. Evidence report/technology assessment 2004(94):1–8.
37.
Martinez JL, Luque-de-Leon E, Ballinas-Oseguera G, Mendez JD, Juarez-Oropeza MA, Roman-Ramos R: Factors predictive of recurrence and mortality after surgical repair of enterocutaneous fistula. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2012, 16(1):156–163; discussion 163–154.CrossRef
38.
Martinez JL, Luque-de-Leon E, Mier J, Blanco-Benavides R, Robledo F: Systematic management of postoperative enterocutaneous fistulas: factors related to outcomes. World J Surg 2008, 32(3):436–443; discussion 444.CrossRefPubMed
39.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ, Committee ASCC: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 2009, 136(5 Suppl):e28.
40.
Dudrick SJ, Palesty JA: Historical highlights of the development of total parenteral nutrition. The Surgical clinics of North America 2011, 91(3):693–717.CrossRefPubMed
41.
Fazio VW, Coutsoftides T, Steiger E: Factors influencing the outcome of treatment of small bowel cutaneous fistula. World J Surg 1983, 7(4):481–488.CrossRefPubMed
42.
Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF: Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. Arch Surg 1999, 134(1):36–42.CrossRefPubMed
43.
Martinez D, Zibari G, Aultman D, McMillan R, Mancini MC, Rush BM, McDonald JC: The outcome of intestinal fistulae: the Louisiana State University Medical Center--Shreveport experience. The American surgeon 1998, 64(3):252–254.PubMed
44.
Garden OJ, Dykes EH, Carter DC: Surgical and nutritional management of postoperative duodenal fistulas. Digestive diseases and sciences 1988, 33(1):30–35.CrossRefPubMed
45.
Davis KG, Johnson EK: Controversies in the care of the enterocutaneous fistula. The Surgical clinics of North America 2013, 93(1):231–250.CrossRefPubMed
46.
Iwasaki K, Harada N, Sasaki K, Yamane S, Iida K, Suzuki K, Hamasaki A, Nasteska D, Shibue K, Joo E et al.: Free fatty acid receptor GPR120 is highly expressed in enteroendocrine K cells of the upper small intestine and has a critical role in GIP secretion after fat ingestion. Endocrinology 2015, 156(3):837–846.CrossRefPubMed
47.
Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM: GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142(5):687–698.CrossRefPubMedPubMedCentral
48.
Cabre E, Manosa M, Gassull MA: Omega-3 fatty acids and inflammatory bowel diseases - a systematic review. The British journal of nutrition 2012, 107 Suppl 2:S240-252.CrossRefPubMed
49.
Hollington P, Mawdsley J, Lim W, Gabe SM, Forbes A, Windsor AJ: An 11-year experience of enterocutaneous fistula. Br J Surg 2004, 91(12):1646–1651.CrossRefPubMed
50.
Visschers RG, Olde Damink SW, van Bekkum M, Winkens B, Soeters PB, van Gemert WG: Health-related quality of life in patients treated for enterocutaneous fistula. Br J Surg 2008, 95(10):1280–1286.CrossRefPubMed
51.
Sitges-Serra A, Jaurrieta E, Sitges-Creus A: Management of postoperative enterocutaneous fistulas: the roles of parenteral nutrition and surgery. Br J Surg 1982, 69(3):147–150.CrossRefPubMed
52.
Conter RL, Roof L, Roslyn JJ: Delayed reconstructive surgery for complex enterocutaneous fistulae. The American surgeon 1988, 54(10):589–593.PubMed
53.
Levy E, Frileux P, Cugnenc PH, Honiger J, Ollivier JM, Parc R: High-output external fistulae of the small bowel: management with continuous enteral nutrition. Br J Surg 1989, 76(7):676–679.CrossRefPubMed
54.
Martinez-Ordaz JL, Luque-de Leon E, Roman-Ramos R, Juarez-Oropeza MA, Mendez-Francisco JD: [Risk factors and evolution of enterocutaneous fistula after terminal ostomy takedown]. Cir Cir 2013, 81(5):394–399.PubMed
55.
Martinez JL, Luque-de-Leon E, Ferat-Osorio E, Estrada-Castellanos A: Predictive value of preoperative serum C-reactive protein for recurrence after definitive surgical repair of enterocutaneous fistula. American journal of surgery 2016.
56.
Stampfl U, Hackert T, Radeleff B, Sommer CM, Stampfl S, Werner J, Buchler MW, Kauczor HU, Richter GM: Percutaneous management of postoperative bile leaks after upper gastrointestinal surgery. Cardiovascular and interventional radiology 2011, 34(4):808–815.CrossRefPubMed
57.
Heller AR, Rossler S, Litz RJ, Stehr SN, Heller SC, Koch R, Koch T: Omega-3 fatty acids improve the diagnosis-related clinical outcome. Crit Care Med 2006, 34(4):972–979.CrossRefPubMed
58.
Wei Z, Wang W, Chen J, Yang D, Yan R, Cai Q: A prospective, randomized, controlled study of omega-3 fish oil fat emulsion-based parenteral nutrition for patients following surgical resection of gastric tumors. Nutrition journal 2014, 13:25.CrossRefPubMedPubMedCentral
59.
Bowden RG, Wilson RL, Deike E, Gentile M: Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2009, 24(4):508–512.CrossRef
60.
Khalfoun B, Thibault F, Watier H, Bardos P, Lebranchu Y: Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6. Advances in experimental medicine and biology 1997, 400B:589–597.PubMed
61.
Fats and fatty acids in human nutrition. Report of an expert consultation. FAO food and nutrition paper 2010, 91:1–166.
Metadata
Title
Effect of Oral ω3-Polyunsaturated Fatty Acids as a Complement Management to Control Fistula Output and Inflammation in Patients With Digestive Fistula
Authors
José Luis Martínez-Ordaz
Ilka Boscó-Gárate
Arturo Cérbulo-Vázquez
Lourdes Arriaga-Pizano
Isabel Wong-Baeza
Patricio Sánchez-Fernandez
Constantino López-Macías
Armando Isibasi
Eduardo Ferat-Osorio
Publication date
01-03-2017
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 3/2017
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-016-3333-6

Other articles of this Issue 3/2017

Journal of Gastrointestinal Surgery 3/2017 Go to the issue

Original Article

Emergent Colectomy Is Independently Associated with Decreased Long-Term Overall Survival in Colon Cancer Patients

Original Article

Enhanced Recovery after Surgery Programs for Liver Resection: a Meta-analysis

Original Article

Pattern of Venous Collateral Development after Splenic Vein Occlusion in an Extended Whipple Procedure (Whipple at the Splenic Artery) and Long-Term Results

Review Article

Operative Treatments for Reflux After Bariatric Surgery: Current and Emerging Management Options

Original Article

Evaluating Trends in the Volume-Outcomes Relationship Following Liver Surgery: Does Regionalization Benefit All Patients the Same?

Original Article

Direct Percutaneous Endoscopic Jejunostomy (DPEJ) Tube Placement: A Single Institution Experience and Outcomes to 30 Days and Beyond